aibioBluejay signs federal distribution partnership with Lovell Government Services
Tickers BJDX
Lovell will be Bluejay's exclusive distributor for federal procurement opportunities that favor veteran-owned small businesses, once its products receive FDA clearance or other required authorization.
Key facts
- Company
- Bluejay Diagnostics, Inc. (NASDAQ: BJDX)
- News type
- Company Updates
- Primary source
- Bluejay Diagnostics, Inc. 8-K (2026-09-08)
On September 8, 2026, Bluejay Diagnostics, Inc. (NASDAQ: BJDX) and Lovell Government Services, Inc. announced a distribution, co-marketing and strategic partnership. The agreement is designed to support the introduction of Bluejay's products into the U.S. federal healthcare market after applicable FDA clearance or other required regulatory authorization. The announcement was also filed with the SEC on Form 8-K the same day.
The terms
Under the agreement, Lovell will serve as Bluejay's exclusive distributor for federal procurement opportunities that require or favor Service-Disabled Veteran-Owned Small Business (SDVOSB) set-aside and preferred status. Those opportunities include the U.S. Department of Veterans Affairs (VA), the Department of Defense (DoD), the Military Health Systems and the Indian Health Service (IHS). Lovell also has non-exclusive rights to take part in open-market federal, state and local government procurement opportunities.
The parties may also collaborate on educational initiatives, conferences, customer engagement and other federal market-development activities. The release does not state payment terms, minimum volumes or any financial commitment by either party.
Neil Dey, Chief Executive Officer of Bluejay Diagnostics, said: "We believe this partnership represents an important step in building Bluejay's commercial infrastructure well ahead of potentially marketing medical devices in the US."
The federal market and Lovell's role
Bluejay cites the size of the federal market as the reason for the partnership. The VA is described as the largest integrated healthcare system in the United States, with approximately 170 major medical centers and 1,193 outpatient clinics and a proposed FY2026 budget of approximately $165.1 billion. The DoD healthcare system includes approximately 45 U.S. military hospitals and 572 military medical clinics, and the Defense Health Agency has a proposed FY2026 budget of approximately $64 billion.
Lovell describes itself as an SDVOSB vendor since 2013 and a five-time Inc. 5000 honoree. Its federal procurement access includes the VA Federal Supply Schedule, GSA Advantage, the GSA Multiple Award Schedule and the Defense Logistics Agency's DAPA and Electronic Catalog (ECAT). According to the release, ECAT is a preferred DoD procurement vehicle for medical supplies and devices and is also used by the VA and IHS.
Financial position
The release does not include financial results. Bluejay's XBRL financial data, drawn from its annual report filed March 6, 2026, shows a net income (loss) of negative $6.8 million for the fiscal year ended December 31, 2025. The same data shows cash used in operations of $6.1 million for 2025 and cash and cash equivalents of $9.6 million at June 30, 2026.
What the partnership does not deliver
The budget figures describe the size of the federal system, not any orders for Bluejay. The product has no FDA clearance, so there is nothing yet to distribute, and the release says the partnership applies only after clearance or other required authorization. The exclusive rights cover only set-aside and preferred-status opportunities, and the release gives no sales target, no minimum purchase and no payment terms. Bluejay lost $6.8 million in 2025 and had $9.6 million of cash at June 30, 2026, per the quarterly report, so building a sales channel for a product that cannot yet be sold draws on a small balance. Bluejay and Lovell may jointly pursue federal market-development initiatives and engage stakeholders in preparation for potential commercialization. Dey said the regulatory, manufacturing and commercial readiness programs should advance in parallel. The release notes that the Symphony platform is an investigational device and is limited by United States law to investigational use. Its first product candidate, the Symphony IL-6 Test, has not been cleared or approved by the FDA.